JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB275091

Anti-FGL1 antibody [EPR24018-27]

  • KO Validated
  • BOND RX™ Validated
  • RabMAb
  • Recombinant
  • 20ul selling size
  • What is this?

Be the first to review this product! Submit a review

|

(3 Publications)

Rabbit Recombinant Monoclonal FGL1 antibody. Suitable for Flow Cyt (Intra), IP, WB, IHC-P and reacts with Human samples. Cited in 3 publications.

View Alternative Names

HFREP1, FGL1, Fibrinogen-like protein 1, HP-041, Hepassocin, Hepatocyte-derived fibrinogen-related protein 1, Liver fibrinogen-related protein 1, HPS, HFREP-1, LFIRE-1

8 Images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FGL1 antibody [EPR24018-27] (AB275091)
  • IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FGL1 antibody [EPR24018-27] (AB275091)

Immunohistochemical analysis of paraffin-embedded human liver tissue labeling FGL1 with ab275091 at 1/500 dilution followed by a ready to use Rabbit specific IHC polymer detection kit HRP/DAB (ab209101). Cytoplasmic staining in human liver (PMID : 11470158). The section was incubated with ab275091 for 30 mins at room temperature. The immunostaining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with Hematoxylin.

Secondary antibody only control : Secondary antibody is ready to use Rabbit specific IHC polymer detection kit HRP/DAB (ab209101).

Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution2) for 20 mins.

Flow Cytometry (Intracellular) - Anti-FGL1 antibody [EPR24018-27] (AB275091)
  • Flow Cyt (Intra)

Unknown

Flow Cytometry (Intracellular) - Anti-FGL1 antibody [EPR24018-27] (AB275091)

Intracellular flow cytometric analysis of 4% paraformaldehyde fixed 90% methanol permeabilized HepG2 (Human hepatocellular carcinoma epithelial cell) cells labelling FGL1 with ab275091 at 1/50 dilution (1ug) (Red) compared with a Rabbit monoclonal IgG (ab172730) isotype control (Black) and an unlabelled control (cells without incubation with primary antibody and secondary antibody) (Blue).

A Goat anti rabbit IgG (Alexa Fluor® 488, ab150077) at 1/2000 dilution was used as the secondary antibody.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FGL1 antibody [EPR24018-27] (AB275091)
  • IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FGL1 antibody [EPR24018-27] (AB275091)

Immunohistochemical analysis of paraffin-embedded human cerebrum tissue labeling FGL1 with ab275091 at 1/500 dilution followed by a ready to use Rabbit specific IHC polymer detection kit HRP/DAB (ab209101). Negative control : No staining in human cerebrum (PMID : 14981537). The section was incubated with ab275091 for 30 mins at room temperature. The immunostaining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with Hematoxylin.

Secondary antibody only control : Secondary antibody is a ready to use Rabbit specific IHC polymer detection kit HRP/DAB (ab209101).

Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution2) for 20 mins.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FGL1 antibody [EPR24018-27] (AB275091)
  • IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FGL1 antibody [EPR24018-27] (AB275091)

Immunohistochemical analysis of paraffin-embedded human hepatocellular carcinoma tissue labeling FGL1 with ab275091 at 1/500 dilution followed by a ready to use Rabbit specific IHC polymer detection kit HRP/DAB (ab209101). Cytoplasmic staining in human hepatocellular carcinoma (PMID : 14981537). The section was incubated with ab275091 for 30 mins at room temperature. The immunostaining was performed on a Leica Biosystems BOND® RX instrument Counterstained with Hematoxylin.

Secondary antibody only control : Secondary antibody is a ready to use Rabbit specific IHC polymer detection kit HRP/DAB (ab209101).

Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution2) for 20 mins.

Immunoprecipitation - Anti-FGL1 antibody [EPR24018-27] (AB275091)
  • IP

Unknown

Immunoprecipitation - Anti-FGL1 antibody [EPR24018-27] (AB275091)

FGL1 was immunoprecipitated from 0.35 mg HepG2 (human hepatocellular carcinoma epithelial cell) whole cell lysate with ab275091 at 1/30 dilution (2ug in 0.35mg lysates). Western blot was performed on the immunoprecipitate using ab275091 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP)(ab131366) was used at 1/5000 dilution.

Lane 1 : HepG2 (human hepatocellular carcinoma epithelial cell) whole cell lysate 10 ug

Lane 2 : ab275091 IP in HepG2 whole cell lysate

Lane 3 : Rabbit monoclonal IgG (ab172730) instead of abID1 in HepG2 whole cell lysate

Blocking and dilution buffer and concentration : 5% NFDM/TBST.

Exposure time : 3 seconds.

All lanes:

Immunoprecipitation - Anti-FGL1 antibody [EPR24018-27] (ab275091)

Predicted band size: 36 kDa

Observed band size: 34 kDa

false

Western blot - Anti-FGL1 antibody [EPR24018-27] (AB275091)
  • WB

Lab

Western blot - Anti-FGL1 antibody [EPR24018-27] (AB275091)

Western blot : Rabbit Monoclonal [EPR24018-27] to FGL1 ab275091 staining at 1/1000 dilution, shown in green; Mouse anti alpha Tubulin ab7291 loading control staining at 1/20000 dilution, shown in magenta. A band was observed at 36 kDa. To generate this image, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3pc Milk in TBS-0.1 % Tween 20 (TBS-T) before incubation with primary antibodies overnight at 4 C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit 800CW and Goat anti-Mouse 680RD at 1/20,000 dilution.

All lanes:

Western blot - Anti-FGL1 antibody [EPR24018-27] (ab275091) at 1/1000 dilution

Lane 1:

Wild-type A549 IL-6 (5 ng/mL, 48 h) + BFA (5 g/mL, last 6 h) at 20 µg

Lane 2:

Wild-type A549 IL-6 (0 ng/mL, 48 h) + BFA (5 g/mL, last 6 h) at 20 µg

Lane 3:

Wild-type A549 BFA (0 g/mL, 6 h) at 20 µg

Lane 4:

FGL1 knockout A549 IL-6 (5 ng/mL, 48 h) + BFA (5 g/mL, last 6 h) at 20 µg

Lane 5:

FGL1 knockout A549 IL-6 (0 ng/mL, 48 h) + BFA (5 g/mL, last 6 h) at 20 µg

Lane 6:

FGL1 knockout A549 BFA (0 g/mL, 6 h) at 20 µg

Lane 7:

HepG2 at 20 µg

Lane 8:

HeLa at 20 µg

Secondary

All lanes:

Goat anti-Rabbit 800CW & Goat anti-Mouse 680RD at 1/20000 dilution

Predicted band size: 36 kDa

Observed band size: 36 kDa

false

Western blot - Anti-FGL1 antibody [EPR24018-27] (AB275091)
  • WB

Unknown

Western blot - Anti-FGL1 antibody [EPR24018-27] (AB275091)

Blocking and dilution buffer : 5% NFDM/TBST.

Exposure time : 15 seconds.

The molecular weight observed is consistent with what has been described in the literature (PMID : 11004478).

Negative control : Human brain (PMID : 11470158).

All lanes:

Western blot - Anti-FGL1 antibody [EPR24018-27] (ab275091) at 1/1000 dilution

Lane 1:

Human liver tissue lysate at 20 µg

Lane 2:

Human brain tissue lysate at 20 µg

Lane 3:

HepG2 (human hepatocellular carcinoma epithelial cell) whole cell lysate at 20 µg

Secondary

All lanes:

VeriBlot for IP secondary antibody(HRP)(<a href='/en-us/products/reagents/veriblot-for-ip-detection-reagent-hrp-ab131366'>ab131366</a>) at 1/1000 dilution

Predicted band size: 36 kDa

Observed band size: 34 kDa

false

Western blot - Anti-FGL1 antibody [EPR24018-27] (AB275091)
  • WB

Unknown

Western blot - Anti-FGL1 antibody [EPR24018-27] (AB275091)

Blocking and dilution buffer : 5% NFDM/TBST.

Exposure time : 3 minutes.

All lanes:

Western blot - Anti-FGL1 antibody [EPR24018-27] (ab275091) at 1/1000 dilution

All lanes:

Huh7 (human hepatocellular carcinoma epithelial cell) whole cell lysate at 20 µg

Secondary

All lanes:

Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/50000 dilution

Predicted band size: 36 kDa

Observed band size: 34 kDa

false

  • Carrier free

    Anti-FGL1 antibody [EPR24018-27] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR24018-27

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

WB, IP, IHC-P, Flow Cyt (Intra)

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "FlowCytIntra" : {"fullname" : "Flow Cytometry (Intracellular)", "shortname":"Flow Cyt (Intra)"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "FlowCytIntra-species-checked": "testedAndGuaranteed", "FlowCytIntra-species-dilution-info": "1/50", "FlowCytIntra-species-notes": "<p></p>", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "<p></p>", "IP-species-checked": "testedAndGuaranteed", "IP-species-dilution-info": "1/30", "IP-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "<p></p>", "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/500", "IHCP-species-notes": "<p></p> Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol." }, "Mouse": { "FlowCytIntra-species-checked": "notRecommended", "FlowCytIntra-species-dilution-info": "", "FlowCytIntra-species-notes": "<p></p>", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "<p></p>", "IP-species-checked": "notRecommended", "IP-species-dilution-info": "1/30", "IP-species-notes": "<p></p>", "WB-species-checked": "notRecommended", "WB-species-dilution-info": "1/1000", "WB-species-notes": "<p></p>", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "1/500", "IHCP-species-notes": "<p></p> Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol." }, "Rat": { "FlowCytIntra-species-checked": "notRecommended", "FlowCytIntra-species-dilution-info": "", "FlowCytIntra-species-notes": "", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "IP-species-checked": "notRecommended", "IP-species-dilution-info": "", "IP-species-notes": "", "WB-species-checked": "notRecommended", "WB-species-dilution-info": "1/1000", "WB-species-notes": "<p></p>", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "1/500", "IHCP-species-notes": "<p></p> Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol." } } }

Product details

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Fibrinogen-like protein 1 (FGL1) also known as Hepassocin plays a significant role in modulating immune responses. FGL1 is a member of the fibrinogen family with a molecular mass of approximately 31 kDa. This protein is widely expressed in the liver and is also found in other tissues like the pancreas and lungs. Its structural homology to fibrinogen suggests potential binding capabilities with similar ligands influencing its mechanical actions in cellular processes.
Biological function summary

FGL1 modulates the immune system and maintains its homeostasis. It functions primarily as a ligand for the immune checkpoint receptor LAG-3. This FGL1-LAG-3 interaction inhibits T-cell activity leading to immune tolerance and helping prevent autoimmunity. FGL1 while not a part of a complex demonstrates significant standalone biological activity by affecting immune responses especially under pathological conditions.

Pathways

FGL1 integrates into the immune regulatory framework. It exerts its effects mainly through the immune checkpoint pathway impacting T-cell regulation. In addition to LAG-3 FGL1 interacts closely with the PD-1/PD-L1 pathway which is also important in checkpoint inhibition and immune evasion mechanisms. These pathways together orchestrate the immune surveillance system and play roles in maintaining immune equilibrium.

FGL1 has received attention in cancer particularly in its role of suppressing anti-tumor immunity. Its interaction with LAG-3 makes it a potential target for cancer immunotherapy as high FGL1 levels correlate with poor prognosis in various cancers. Additionally it has implications in autoimmune diseases where its regulation of T-cell activity prevents excessive immune responses. By modulating LAG-3 activity FGL1 emerges as a therapeutic target of interest in autoimmune conditions presenting new opportunities for managing such disorders.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Immune suppressive molecule that inhibits antigen-specific T-cell activation by acting as a ligand of LAG3 (PubMed : 30580966, PubMed : 35761082, PubMed : 40101708). LAG3-binding initiates a signaling that inhibits the T-cell receptor (TCR) in the immunological synapse, preventing T-cell activation (PubMed : 30580966). Binds LAG3 independently from MHC class II (MHC-II) (PubMed : 30580966, PubMed : 35761082). Secreted by, and promotes growth of, hepatocytes (PubMed : 11470158, PubMed : 19880967).
See full target information FGL1

Publications (3)

Recent publications for all applications. Explore the full list and refine your search

Frontiers in immunology 15:1302761 PubMed38390332

2024

Immune checkpoint ligands expressed on mature high endothelial venules predict poor prognosis of NSCLC: have a relationship with CD8 T lymphocytes infiltration.

Applications

Unspecified application

Species

Unspecified reactive species

Jing Luo,Xiuhuan Shi,Yumeng Liu,Jian Wang,Hao Wang,Xuena Yang,Qian Sun,Zhenzhen Hui,Feng Wei,Xiubao Ren,Hua Zhao

Frontiers in immunology 14:1112672 PubMed36993960

2023

Fibrinogen-like protein 1 promotes liver-resident memory T-cell exhaustion in hepatocellular carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Changjie Yang,Qiwei Qian,Yudong Zhao,Bingyuan Huang,Ruilin Chen,Qiyu Gong,Hao Ji,Chenchen Wang,Lei Xia,Zhengrui You,Jianjun Zhang,Xiaosong Chen

The Journal of international medical research 50:3000605221126874 PubMed36173010

2022

Fibrinogen like protein-1 knockdown suppresses the proliferation and metastasis of TU-686 cells and sensitizes laryngeal cancer to LAG-3 blockade.

Applications

Unspecified application

Species

Unspecified reactive species

Jiameng Huang,Qiang Huang,Jiyao Xue,Huiqin Liu,Yang Guo,Hui Chen,Liang Zhou
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com